any salt or ester of zoledronic acid.
“[our] study demonstrates that anti-resorptive drugs [like zoledronate] are effective outside the narrow confines of women with osteoporosis,” says reid. “therefore, this study opens the possibility of using this group of agents in women whose bone density or fracture risk is not necessarily as high as many guidelines recommend. it also validates the practice of treating women at moderate to high fracture risk even if their bone density is in the osteopenic range. i think [zoledronate] is a sensible way forward in older women who wish to reduce their fracture risk. not only is zoledronate effective in reducing fracture risk across a broad group of older women, but it also appears to have beneficial effects on the risk of cardiovascular disease and cancers.” everydayhealth.com
dr. drake says: "in prostate cancer, zoledronate is the best-studied bisphosphonate. zoledronate has been shown to decrease bone loss and fracture risk, as well as to reduce bone loss induced by gonadotropin-releasing hormone agonist. more recently, denosumab was shown to increase bmd in patients with prostate cancer receiving adt and to prolong the time to first skeleton-related event relative to zoledronate." mayoclinic.org
conditions that are risk factors associated with aseptic necrosis include alcoholism, cortisone medications, cushing's syndrome, radiation exposure, smoking cigarettes, sickle cell disease, pancreatitis, hyperlipidemia, caisson's disease (dysbarism), gaucher disease, and systemic lupus erythematosus. aseptic necrosis of the jawbone has been rarely reported in association with the use of bisphosphonate medication, particularly intravenously including zoledronate (zometa) and pamidronate (aredia). medicinenet.com
another monoclonal antibody, denosumab (xgeva), inhibits the receptor activator of nuclear factor kappa beta ligand. a meta-analysis of three phase iii trials (nct00321464, nct00321620, and nct00330759) comparing zoledronate versus denosumab for management of bone metastases suggests that denosumab is similar to zoledronate in reducing the risk of a first skeletal-related event. medpagetoday.com
bisphosphonates are drugs that inhibit bone turnover. one of several bisphosphonates—alendronate, etidronate, pamidronate, risedronate, tiludronate, or zoledronate—can be used to slow the progression of paget disease. except for pamidronate and zoledronate, which are usually given by vein (intravenously), these drugs are given by mouth. these drugs are given for the following: merckmanuals.com